Delcath Systems Inc (DCTH) 0.23 $DCTH
Delcath Issues $35 Million in Senior Convertible Notes to Support Melphalan/HDS Clinical Development and CHEMOSAT European Commercialization
PR Newswire - Tue Jun 07, 7:00AM CDT
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces it has entered into a securities purchase agreement with an institutional investor to issue $35.0 million of senior convertible notes (the Notes) and related common stock purchase warrants. The Notes will be issued at an 8% original issue discount. The aggregate proceeds of $32.2 million will be used to fund the Company's ongoing operations, commercial activities and clinical development programs, including its global Phase 3 trial with Melphalan/HDS in hepatic dominant ocular melanoma (the FOCUS Trial) and its global Phase 2 program with Melphalan/HDS in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).
DCTH: 0.23 (unch)
Delcath Announces Launch of CHEMOSAT at the HM Sanchinarro University Hospital in Madrid
PR Newswire - Wed Jun 01, 7:00AM CDT
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that the General and Digestive Surgery team at HM Sanchinarro University Hospital, led by Emilio Vicente, M.D. and Yolanda Quijano, M.D., has successfully launched the hospital's Hepatic Chemosaturation Program. The Sanchinarro team successfully performed three procedures with Delcath's proprietary Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (CHEMOSAT® or Melphalan/HDS). The team at HM Sanchinarro is using the CHEMOSAT procedure in peripheral cholangiocarcinoma, neuroendocrine tumours and colorectal liver metastases. HM Sanchinarro University Hospital is the second center in Spain to offer the treatment.
DCTH: 0.23 (unch)
Delcath to Present at the 6th Annual LD Micro Invitational
PR Newswire - Tue May 31, 7:00AM CDT
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that Company management will participate at the 6th Annual LD Micro Invitational taking place from June 7-9, 2016 in Los Angeles. Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Delcath, will present a corporate overview on June 8th at 12:30 p.m. Pacific time.
DCTH: 0.23 (unch)
Delcath Announces First Quarter Financial Results
PR Newswire - Wed May 04, 7:00AM CDT
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces financial results for the three months ended March 31, 2016.
DCTH: 0.23 (unch)
Leading U.S. Cancer Centers Join Delcath's Focus Phase 3 Trial For Patients With Hepatic Dominant Ocular Melanoma
PR Newswire - Tue May 03, 7:00AM CDT
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers, announces that John Wayne Cancer Institute in Los Angeles, California and Duke Cancer Institute in Durham, North Carolina have been activated as clinical trial sites in the Company's FOCUS Phase 3 Clinical Trial for Patients with Hepatic Dominant Ocular Melanoma (the FOCUS Trial). The prestigious centers join Moffitt Cancer Center in Tampa, Florida as active participants in the FOCUS Trial. Delcath plans to include approximately 30 cancer centers in the United States and Europe in the FOCUS Trial.
DCTH: 0.23 (unch)
Delcath Announces First CHEMOSAT® Procedures In Turkey
PR Newswire - Fri Apr 08, 7:00AM CDT
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers, announces that the Hacettepe University Clinic in Ankara, Turkey has been activated as a treatment center for the Delcath Hepatic CHEMOSAT Delivery System (CHEMOSAT®) for the treatment of cancers of the liver. Hacettepe University Clinic successfully completed its first CHEMOSAT treatments in March, and the center represents the first CHEMOSAT commercial location to be activated outside of the European Union.
DCTH: 0.23 (unch)
Delcath Announces 2015 Fourth Quarter and Full Year Financial Results
PR Newswire - Mon Mar 21, 7:00AM CDT
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces financial results for the three and 12 months ended December 31, 2015.
DCTH: 0.23 (unch)
Delcath to Present at the 28th Annual ROTH Conference
PR Newswire - Mon Mar 07, 7:00AM CST
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that Company management will participate at the 28th Annual ROTH Capital Partners Conference taking place from March 13th-16th, 2016 in Dana Point, California. Jennifer K. Simpson, Ph.D., MSN, CRNP, President, and Chief Executive Officer of Delcath, will present a corporate overview on March 14th at 4:00 p.m. Pacific time.
DCTH: 0.23 (unch)
Delcath Announces Beginning Of Patient Enrollment In Phase 3 Focus Trial
PR Newswire - Wed Feb 10, 7:30AM CST
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that patient enrollment has begun in the Company's Phase 3 clinical trial: "A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma" (the FOCUS Trial). The first patient was evaluated and randomized into the trial at the Moffitt Cancer Center in Tampa, Florida.
DCTH: 0.23 (unch)
Delcath Systems to Present at Upcoming Investor Conferences
PR Newswire - Thu Feb 04, 7:00AM CST
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that Company management will participate at two upcoming investor conferences in February.
DCTH: 0.23 (unch)
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review 2015
M2 - Fri Jan 29, 10:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/g3ggw6/bile_duct_cancer) has announced the addition of the "Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Bile Duct Cancer (Cholangiocarcinoma) Overview - Therapeutics Development - Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) - Overview - Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis - Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Development by Companies - Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Investigation by Universities/Institutes - Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Bile Duct Cancer (Cholangiocarcinoma) - Products under Development by Companies - Bile Duct Cancer (Cholangiocarcinoma) - Products under Investigation by Universities/Institutes - Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development Companies Mentioned: - 4SC AG - Agios Pharmaceuticals, Inc. - Ariad Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Aslan Pharmaceuticals Pte. Ltd. - Bayer AG - BIND Therapeutics, Inc. - Blueprint Medicines - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - CellAct Pharma GmbH - Cellceutix Corporation - Concordia Healthcare Corp. - Cornerstone Pharmaceuticals, Inc. - Delcath Systems, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Johnson & Johnson - Komipharm International Co., Ltd. - (20 More) For more information visit http://www.researchandmarkets.com/research/g3...uct_cancer
BPMC: 19.65 (-0.87), ARQL: 1.78 (unch), LLY: 73.95 (-0.48), BIND: 0.40 (-0.01), BMY: 72.65 (-0.08), JNJ: 117.01 (+0.01), AGIO: 50.35 (-5.87), DCTH: 0.23 (unch), EXEL: 7.38 (+0.01), ARRY: 3.51 (-0.01), CELGZ: 1.46 (-0.04), CXRX: 23.80 (-0.67)
Delcath Announces Initiation Of Phase 3 Trial Of Melphalan/HDS System For Treatment Of Hepatic Dominant Ocular Melanoma
PR Newswire - Wed Jan 20, 7:00AM CST
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces the initiation of a Phase 3 clinical trial of Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) for the treatment of patients with hepatic dominant ocular melanoma (OM).
DCTH: 0.23 (unch)
Delcath Announces Special Protocol Assessment Agreement With FDA For New Phase 3 Trial In Hepatic Dominant Ocular Melanoma
PR Newswire - Tue Jan 19, 7:00AM CST
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that the Company has reached a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the design of Delcath's new Phase 3 clinical trial of Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) to treat patients with hepatic dominant ocular melanoma. The SPA provides agreement that the Phase 3 trial design adequately addresses objectives that, if met, would support the submission for regulatory approval of Melphalan/HDS.
DCTH: 0.23 (unch)
Delcath To Present At NobleCon12 Investor Conference
PR Newswire - Fri Jan 15, 9:18AM CST
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that Company management will participate in the upcoming NobleCon12 - Noble Financial Capital Markets' Twelfth Annual Investor Conference, which will be held at Club Med in Palm Springs, Florida, January 17-20, 2016. Jennifer Simpson, PhD, MSN, CRNP, Delcath's President and Chief Executive Officer, will present a corporate overview and update on Wednesday, January 20, 2016 at 10:00 am Eastern time.
DCTH: 0.23 (unch)
Review of Delcath Melphalan/HDS System Published in "Cardiovascular & Interventional Radiology"
PR Newswire - Mon Jan 11, 7:30AM CST
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that a review of the Delcath Hepatic Delivery System (Melphalan/HDS) for the treatment of patients with liver cancers has been published in Cardiovascular & Interventional Radiology (CVIR), a leading peer-reviewed medical journal.
DCTH: 0.23 (unch)
Delcath Prior Phase 3 Trial Results Published In Annals Of Surgical Oncology
PR Newswire - Wed Dec 09, 7:59AM CST
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that the results from its Phase 3 clinical study of the Delcath Hepatic Delivery System (Melphalan/HDS) for the treatment of melanoma patients with liver metastases, have been published in the December issue of the prestigious, peer-reviewed journal, Annals of Surgical Oncology. The study completed enrollment in 2009 and used an earlier version of the Melphalan/HDS and procedure. Melphalan/HDS is investigational in the United States.
DCTH: 0.23 (unch)
enGene Inc. annouces the appointment of Dr. Dennis H. Langer to the company's Board of Directors
CNW Group - Tue Dec 08, 8:01AM CST
enGene, Inc., a gene therapy company focused on development of therapeutics using its proprietary "Gene Pill" and enema gene delivery platform, today announced the appointment of Dr. Dennis H. Langer to its Board of Directors.
NTEC: 4.51 (-0.12), MYGN: 30.95 (-3.07), DRNA: 3.45 (-0.21), SHPG: 177.10 (-6.85), MRK: 56.81 (-0.37), DCTH: 0.23 (unch)
Delcath Announces CHEMOSAT Review Accepted for Publication in Cardiovascular and Interventional Radiology
PR Newswire - Tue Dec 08, 7:00AM CST
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that a review study of treatment of liver cancers with the Delcath Hepatic CHEMOSAT® Delivery System (Melphalan/HDS) has been accepted for publication in the Cardiovascular and Interventional Radiology (CVIR), a leading peer-reviewed medical journal.
DCTH: 0.23 (unch)
Delcath Announces CHEMOSAT Treatment Milestones In Europe
PR Newswire - Wed Dec 02, 7:00AM CST
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that physicians in Europe have completed over 250 treatments with Delcath Hepatic CHEMOSAT® Delivery System (CHEMOSAT) since the second generation of CHEMOSAT was launched. Physicians in Europe have used CHEMOSAT in both commercial and clinical settings to treat patients for a wide variety of cancers in the liver, including ocular melanoma liver metastases, hepatocellular carcinoma and intrahepatic cholangiocarcinoma, and liver metastases from colorectal cancer, breast cancer and others.
DCTH: 0.23 (unch)
Delcath Issues $35 Million in Senior Convertible Notes to Support Melphalan/HDS Clinical Development and CHEMOSAT European Commercialization
PR Newswire - Tue Jun 07, 7:00AM CDT
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces it has entered into a securities purchase agreement with an institutional investor to issue $35.0 million of senior convertible notes (the Notes) and related common stock purchase warrants. The Notes will be issued at an 8% original issue discount. The aggregate proceeds of $32.2 million will be used to fund the Company's ongoing operations, commercial activities and clinical development programs, including its global Phase 3 trial with Melphalan/HDS in hepatic dominant ocular melanoma (the FOCUS Trial) and its global Phase 2 program with Melphalan/HDS in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).
DCTH: 0.23 (unch)
Delcath Announces Launch of CHEMOSAT at the HM Sanchinarro University Hospital in Madrid
PR Newswire - Wed Jun 01, 7:00AM CDT
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that the General and Digestive Surgery team at HM Sanchinarro University Hospital, led by Emilio Vicente, M.D. and Yolanda Quijano, M.D., has successfully launched the hospital's Hepatic Chemosaturation Program. The Sanchinarro team successfully performed three procedures with Delcath's proprietary Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (CHEMOSAT® or Melphalan/HDS). The team at HM Sanchinarro is using the CHEMOSAT procedure in peripheral cholangiocarcinoma, neuroendocrine tumours and colorectal liver metastases. HM Sanchinarro University Hospital is the second center in Spain to offer the treatment.
DCTH: 0.23 (unch)
Delcath to Present at the 6th Annual LD Micro Invitational
PR Newswire - Tue May 31, 7:00AM CDT
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that Company management will participate at the 6th Annual LD Micro Invitational taking place from June 7-9, 2016 in Los Angeles. Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Delcath, will present a corporate overview on June 8th at 12:30 p.m. Pacific time.
DCTH: 0.23 (unch)
Delcath Announces First Quarter Financial Results
PR Newswire - Wed May 04, 7:00AM CDT
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces financial results for the three months ended March 31, 2016.
DCTH: 0.23 (unch)
Leading U.S. Cancer Centers Join Delcath's Focus Phase 3 Trial For Patients With Hepatic Dominant Ocular Melanoma
PR Newswire - Tue May 03, 7:00AM CDT
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers, announces that John Wayne Cancer Institute in Los Angeles, California and Duke Cancer Institute in Durham, North Carolina have been activated as clinical trial sites in the Company's FOCUS Phase 3 Clinical Trial for Patients with Hepatic Dominant Ocular Melanoma (the FOCUS Trial). The prestigious centers join Moffitt Cancer Center in Tampa, Florida as active participants in the FOCUS Trial. Delcath plans to include approximately 30 cancer centers in the United States and Europe in the FOCUS Trial.
DCTH: 0.23 (unch)
Delcath Announces First CHEMOSAT® Procedures In Turkey
PR Newswire - Fri Apr 08, 7:00AM CDT
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers, announces that the Hacettepe University Clinic in Ankara, Turkey has been activated as a treatment center for the Delcath Hepatic CHEMOSAT Delivery System (CHEMOSAT®) for the treatment of cancers of the liver. Hacettepe University Clinic successfully completed its first CHEMOSAT treatments in March, and the center represents the first CHEMOSAT commercial location to be activated outside of the European Union.
DCTH: 0.23 (unch)
Delcath Announces 2015 Fourth Quarter and Full Year Financial Results
PR Newswire - Mon Mar 21, 7:00AM CDT
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces financial results for the three and 12 months ended December 31, 2015.
DCTH: 0.23 (unch)
Delcath to Present at the 28th Annual ROTH Conference
PR Newswire - Mon Mar 07, 7:00AM CST
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that Company management will participate at the 28th Annual ROTH Capital Partners Conference taking place from March 13th-16th, 2016 in Dana Point, California. Jennifer K. Simpson, Ph.D., MSN, CRNP, President, and Chief Executive Officer of Delcath, will present a corporate overview on March 14th at 4:00 p.m. Pacific time.
DCTH: 0.23 (unch)
Delcath Announces Beginning Of Patient Enrollment In Phase 3 Focus Trial
PR Newswire - Wed Feb 10, 7:30AM CST
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that patient enrollment has begun in the Company's Phase 3 clinical trial: "A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma" (the FOCUS Trial). The first patient was evaluated and randomized into the trial at the Moffitt Cancer Center in Tampa, Florida.
DCTH: 0.23 (unch)
Delcath Systems to Present at Upcoming Investor Conferences
PR Newswire - Thu Feb 04, 7:00AM CST
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that Company management will participate at two upcoming investor conferences in February.
DCTH: 0.23 (unch)
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review 2015
M2 - Fri Jan 29, 10:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/g3ggw6/bile_duct_cancer) has announced the addition of the "Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Bile Duct Cancer (Cholangiocarcinoma) Overview - Therapeutics Development - Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) - Overview - Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis - Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Development by Companies - Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Investigation by Universities/Institutes - Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Bile Duct Cancer (Cholangiocarcinoma) - Products under Development by Companies - Bile Duct Cancer (Cholangiocarcinoma) - Products under Investigation by Universities/Institutes - Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development Companies Mentioned: - 4SC AG - Agios Pharmaceuticals, Inc. - Ariad Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Aslan Pharmaceuticals Pte. Ltd. - Bayer AG - BIND Therapeutics, Inc. - Blueprint Medicines - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - CellAct Pharma GmbH - Cellceutix Corporation - Concordia Healthcare Corp. - Cornerstone Pharmaceuticals, Inc. - Delcath Systems, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Johnson & Johnson - Komipharm International Co., Ltd. - (20 More) For more information visit http://www.researchandmarkets.com/research/g3...uct_cancer
BPMC: 19.65 (-0.87), ARQL: 1.78 (unch), LLY: 73.95 (-0.48), BIND: 0.40 (-0.01), BMY: 72.65 (-0.08), JNJ: 117.01 (+0.01), AGIO: 50.35 (-5.87), DCTH: 0.23 (unch), EXEL: 7.38 (+0.01), ARRY: 3.51 (-0.01), CELGZ: 1.46 (-0.04), CXRX: 23.80 (-0.67)
Delcath Announces Initiation Of Phase 3 Trial Of Melphalan/HDS System For Treatment Of Hepatic Dominant Ocular Melanoma
PR Newswire - Wed Jan 20, 7:00AM CST
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces the initiation of a Phase 3 clinical trial of Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) for the treatment of patients with hepatic dominant ocular melanoma (OM).
DCTH: 0.23 (unch)
Delcath Announces Special Protocol Assessment Agreement With FDA For New Phase 3 Trial In Hepatic Dominant Ocular Melanoma
PR Newswire - Tue Jan 19, 7:00AM CST
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that the Company has reached a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the design of Delcath's new Phase 3 clinical trial of Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) to treat patients with hepatic dominant ocular melanoma. The SPA provides agreement that the Phase 3 trial design adequately addresses objectives that, if met, would support the submission for regulatory approval of Melphalan/HDS.
DCTH: 0.23 (unch)
Delcath To Present At NobleCon12 Investor Conference
PR Newswire - Fri Jan 15, 9:18AM CST
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that Company management will participate in the upcoming NobleCon12 - Noble Financial Capital Markets' Twelfth Annual Investor Conference, which will be held at Club Med in Palm Springs, Florida, January 17-20, 2016. Jennifer Simpson, PhD, MSN, CRNP, Delcath's President and Chief Executive Officer, will present a corporate overview and update on Wednesday, January 20, 2016 at 10:00 am Eastern time.
DCTH: 0.23 (unch)
Review of Delcath Melphalan/HDS System Published in "Cardiovascular & Interventional Radiology"
PR Newswire - Mon Jan 11, 7:30AM CST
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that a review of the Delcath Hepatic Delivery System (Melphalan/HDS) for the treatment of patients with liver cancers has been published in Cardiovascular & Interventional Radiology (CVIR), a leading peer-reviewed medical journal.
DCTH: 0.23 (unch)
Delcath Prior Phase 3 Trial Results Published In Annals Of Surgical Oncology
PR Newswire - Wed Dec 09, 7:59AM CST
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that the results from its Phase 3 clinical study of the Delcath Hepatic Delivery System (Melphalan/HDS) for the treatment of melanoma patients with liver metastases, have been published in the December issue of the prestigious, peer-reviewed journal, Annals of Surgical Oncology. The study completed enrollment in 2009 and used an earlier version of the Melphalan/HDS and procedure. Melphalan/HDS is investigational in the United States.
DCTH: 0.23 (unch)
enGene Inc. annouces the appointment of Dr. Dennis H. Langer to the company's Board of Directors
CNW Group - Tue Dec 08, 8:01AM CST
enGene, Inc., a gene therapy company focused on development of therapeutics using its proprietary "Gene Pill" and enema gene delivery platform, today announced the appointment of Dr. Dennis H. Langer to its Board of Directors.
NTEC: 4.51 (-0.12), MYGN: 30.95 (-3.07), DRNA: 3.45 (-0.21), SHPG: 177.10 (-6.85), MRK: 56.81 (-0.37), DCTH: 0.23 (unch)
Delcath Announces CHEMOSAT Review Accepted for Publication in Cardiovascular and Interventional Radiology
PR Newswire - Tue Dec 08, 7:00AM CST
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that a review study of treatment of liver cancers with the Delcath Hepatic CHEMOSAT® Delivery System (Melphalan/HDS) has been accepted for publication in the Cardiovascular and Interventional Radiology (CVIR), a leading peer-reviewed medical journal.
DCTH: 0.23 (unch)
Delcath Announces CHEMOSAT Treatment Milestones In Europe
PR Newswire - Wed Dec 02, 7:00AM CST
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that physicians in Europe have completed over 250 treatments with Delcath Hepatic CHEMOSAT® Delivery System (CHEMOSAT) since the second generation of CHEMOSAT was launched. Physicians in Europe have used CHEMOSAT in both commercial and clinical settings to treat patients for a wide variety of cancers in the liver, including ocular melanoma liver metastases, hepatocellular carcinoma and intrahepatic cholangiocarcinoma, and liver metastases from colorectal cancer, breast cancer and others.
DCTH: 0.23 (unch)
